Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
12 nov. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
Vallon Pharmaceuticals to Present at the Virtual Investor Roundtable Event
11 nov. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Live moderated video webcast discussion among members of management and ADHD and abuse expert, Stephen V. Faraone, Ph.D., on Thursday, November 18th at 3:00 PM ET PHILADELPHIA, PA, Nov. 11, 2021...
Vallon Pharmaceuticals to Present at the H.C. Wainwright 7th Annual Israel Virtual Conference
10 nov. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Live video webcast presentation on Monday, November 15th at 8:30 am ET PHILADELPHIA, PA, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...
Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting
01 nov. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Results suggest that developing stimulant formulations with abuse deterrent properties by non-oral routes may potentially reduce negative consequences of misuse, abuse, and diversion of stimulant...
Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements
12 oct. 2021 08h35 HE
|
Vallon Pharmaceuticals Inc.
- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board
14 sept. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Inaugural appointments include globally renowned leaders and experts on attention-deficit/hyperactivity disorder (ADHD) and stimulant abuse PHILADELPHIA, PA, Sept. 14, 2021 (GLOBE NEWSWIRE)...
Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit
11 août 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
Live video webcast with David Baker, President and CEO of Vallon, on Wednesday, August 18th 12:30 PM ET PHILADELPHIA, PA, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ:...
Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
10 août 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Company continues to drive enrollment in pivotal intranasal abuse study evaluating ADAIR toward completion before year-end 2021 - ADAIR targeting the large and growing Adderall® segment of the...
Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR
13 juil. 2021 08h05 HE
|
Vallon Pharmaceuticals Inc.
- Patent bolsters intellectual property protection as Company’s partner, MEDICE, works to develop and potentially commercialize ADAIR in Europe and the UK PHILADELPHIA, PA, July 13, 2021 (GLOBE...
Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
13 mai 2021 09h15 HE
|
Vallon Pharmaceuticals Inc.
- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...